Tags

Type your tag names separated by a space and hit enter

Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Bone Marrow Transplant. 1996 May; 17(5):685-9.BM

Abstract

This study reviews results of a radiation-free preparative regimen consisting of busulfan and cyclophosphamide in 65 unrelated allogeneic bone marrow transplant recipients. Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia. The patients were transplanted at four different medical centers from July 1988 to November 1992. Ages ranged 4-48 years (median 32). Fifty-seven patients received busulfan 16 mg/kg and cyclophosphamide 120 mg/kg, and eight received busulfan at doses between 15 and 17 mg/kg and cyclophosphamide at doses 100-200 mg/kg as preparative regimens. All patients received cyclosporine for graft-versus-host disease prophylaxis; in addition 46 patients received corticosteroid, 38 methotrexate, six anti-CD5 ricin A-immunotoxin, and four T cell-depleted bone marrow. Median follow-up of survivors was 53 months (range 15-68 months). Four year actuarial survival was 24 +/- 12%. Four-year survival based on disease was 29 +/- 27% for chronic myelogenous leukemia (CML) in chronic phase, 20 +/- 9% for chronic myelogenous leukemia in accelerated phase, 0% for chronic myelogenous leukemia in blast phase, 32 +/- 40% for acute leukemia, and 38 +/- 34% for myelodysplasia. Actuarial survival was 66 +/- 40% in patients age < 20 years, vs 23 +/- 13% for patients ages 20 to 40, and 10 +/- 14% for patients age > 40 years. Fifty patients (88%) engrafted. Graft failure occurred in eight patients. Acute graft-versus-host disease grade II-IV occurred in 36 (72%). Two patients relapsed after engraftment with the donor cells and died of leukemia within a month of relapse. The most common causes of death were graft-versus-host disease (37%), and transplant-related toxicity (59%); relapse (4%) was a rare cause of death. Busulfan/cyclophosphamide is an effective preparative regimen in unrelated bone marrow transplantation permitting adequate engraftment and a low relapse rate. Best results are observed in patients less than 20 years old.

Authors+Show Affiliations

Sahebi F
Transplantation Biology Unit, UCLA Hospital and Clinics, USA.
Copelan E
No affiliation info available
Crilley P
No affiliation info available
Bolwell B
No affiliation info available
Avalos B
No affiliation info available
Klein J
No affiliation info available
Territo M
No affiliation info available
Gajewski J
No affiliation info available

MeSH

AdolescentAdultAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBusulfanChildChild, PreschoolCyclophosphamideGraft SurvivalGraft vs Host DiseaseHumansLeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiddle AgedMyelodysplastic SyndromesRecurrenceTransplantation ConditioningTransplantation, Homologous

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8733682

Citation

Sahebi, F, et al. "Unrelated Allogeneic Bone Marrow Transplantation Using High-dose Busulfan and Cyclophosphamide (BU-CY) for the Preparative Regimen." Bone Marrow Transplantation, vol. 17, no. 5, 1996, pp. 685-9.
Sahebi F, Copelan E, Crilley P, et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplant. 1996;17(5):685-9.
Sahebi, F., Copelan, E., Crilley, P., Bolwell, B., Avalos, B., Klein, J., Territo, M., & Gajewski, J. (1996). Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplantation, 17(5), 685-9.
Sahebi F, et al. Unrelated Allogeneic Bone Marrow Transplantation Using High-dose Busulfan and Cyclophosphamide (BU-CY) for the Preparative Regimen. Bone Marrow Transplant. 1996;17(5):685-9. PubMed PMID: 8733682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. AU - Sahebi,F, AU - Copelan,E, AU - Crilley,P, AU - Bolwell,B, AU - Avalos,B, AU - Klein,J, AU - Territo,M, AU - Gajewski,J, PY - 1996/5/1/pubmed PY - 1996/5/1/medline PY - 1996/5/1/entrez SP - 685 EP - 9 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 17 IS - 5 N2 - This study reviews results of a radiation-free preparative regimen consisting of busulfan and cyclophosphamide in 65 unrelated allogeneic bone marrow transplant recipients. Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia. The patients were transplanted at four different medical centers from July 1988 to November 1992. Ages ranged 4-48 years (median 32). Fifty-seven patients received busulfan 16 mg/kg and cyclophosphamide 120 mg/kg, and eight received busulfan at doses between 15 and 17 mg/kg and cyclophosphamide at doses 100-200 mg/kg as preparative regimens. All patients received cyclosporine for graft-versus-host disease prophylaxis; in addition 46 patients received corticosteroid, 38 methotrexate, six anti-CD5 ricin A-immunotoxin, and four T cell-depleted bone marrow. Median follow-up of survivors was 53 months (range 15-68 months). Four year actuarial survival was 24 +/- 12%. Four-year survival based on disease was 29 +/- 27% for chronic myelogenous leukemia (CML) in chronic phase, 20 +/- 9% for chronic myelogenous leukemia in accelerated phase, 0% for chronic myelogenous leukemia in blast phase, 32 +/- 40% for acute leukemia, and 38 +/- 34% for myelodysplasia. Actuarial survival was 66 +/- 40% in patients age < 20 years, vs 23 +/- 13% for patients ages 20 to 40, and 10 +/- 14% for patients age > 40 years. Fifty patients (88%) engrafted. Graft failure occurred in eight patients. Acute graft-versus-host disease grade II-IV occurred in 36 (72%). Two patients relapsed after engraftment with the donor cells and died of leukemia within a month of relapse. The most common causes of death were graft-versus-host disease (37%), and transplant-related toxicity (59%); relapse (4%) was a rare cause of death. Busulfan/cyclophosphamide is an effective preparative regimen in unrelated bone marrow transplantation permitting adequate engraftment and a low relapse rate. Best results are observed in patients less than 20 years old. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8733682/Unrelated_allogeneic_bone_marrow_transplantation_using_high_dose_busulfan_and_cyclophosphamide__BU_CY__for_the_preparative_regimen_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -